Skip to main content
Premium Trial:

Request an Annual Quote

QuantuMDx Raises $8.4M to Support Development of POC MDx Device

NEW YORK (GenomeWeb News) – British molecular diagnostics company QuantuMDx has closed an $8.4 million investment round to further the development of a device for point-of-care testing, the firm said today.

Private investors and the University of Newcastle upon Tyne contributed to the round, which will support the optimization of Q-POC, QuantuMDx's handheld DNA sequencing and genotyping device, and allow the company to flesh out its R&D team and advisory board.

QuatntuMDx CEO Elaine Warburton said in a statement that the six-year-old, Newcastle-based firm plans to unveil a prototype of the device later this year. "[W]e anticipate much interest from life ccience and pharma companies seeking a low-cost, high-quality POC platform for diagnostics and to support drug development," she said.

QuantuMDx moved from basic research to an engineering phase last year, and is now beginning to test its alpha prototype. The device performs sample preparation, extraction, amplification, and uses a nanowire biosensor to detect DNA sequences of interest in less than 15 minutes, according to the firm.

The company said that field trials will begin early next year for Q-POC's first assays: a test for malaria subtyping and drug-resistance testing developed in partnership with NGOs and hospitals in several African countries, and a companion diagnostic for warfarin within the UK's National Health Service. The firm hopes to launch both assays later in 2015.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.